Abstract 189P
Background
The randomized, 2-part, open-label, phase 3 LEAP-014 study (NCT04949256) is being conducted to evaluate the safety and efficacy of len + pembro + chemo vs pembro + chemo in patients with previously untreated metastatic ESCC. Results from the safety run-in cohort (part 1) are reported.
Methods
Eligible patients had histologically or cytologically confirmed previously untreated metastatic ESCC, measurable disease per RECIST v1.1 by investigator assessment, and ECOG PS score 0 or 1. In part 1, patients received induction with pembro 400 mg IV Q6W ×2 cycles + len 8 mg PO QD + chemo (cisplatin + 5-FU [FP cohort] Q3W ×4 cycles or paclitaxel + cisplatin [TP cohort] Q3W ×4 cycles) and consolidation with pembro 400 mg IV Q6W for ≤16 cycles + len 20 mg PO QD. Treatment continued until disease progression or unacceptable toxicity. Primary end points for part 1 were dose-limiting toxicities (DLTs), adverse events (AEs), and discontinuations due to AEs. DLTs were evaluated for 21 days after the first dose; if ≥3 DLTs occurred in the TP or FP cohort, then part 2 could be delayed to further examine safety data and consider study design changes.
Results
At data cutoff (February 2, 2023), 13 patients were treated (FP cohort, n = 7; TP cohort, n = 6). Median time from first dose to data cutoff was 16.6 months (range, 15.9-17.3) and 5.6 months (4.6-6.2) with len + pembro + FP and len + pembro + TP, respectively. Median (range) age was 64 years (43-77) and 66 years (53-71), respectively. One DLT of grade 3 acute kidney injury associated with increased creatinine level and 1 DLT of grade 3 hypokalemia occurred in the FP cohort; no DLTs were reported in the TP cohort. No patient discontinued because of a DLT and no treatment-related deaths occurred. Preliminary efficacy results will be reported.
Conclusions
Part 1 (safety run-in) of LEAP-014 showed that len + pembro + chemo had acceptable safety and tolerability in patients with previously untreated metastatic ESCC, allowing initiation of part 2. Part 2 is ongoing and is evaluating the efficacy and safety of len + pembro + chemo vs pembro + chemo as first-line therapy for patients with metastatic ESCC.
Clinical trial identification
NCT0494926.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Obinna Ezeokoli, PhD, and Andrea Humphries, PhD, CMPP, of ApotheCom (Yardley, PA,USA). This assistance was funded by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,Rahway, NJ, USA.
Legal entity responsible for the study
Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
S. Yamamoto: Financial Interests, Personal, Invited Speaker: Ono, Bristol Myers Squibb, MSD. C. Rojas: Financial Interests, Personal, Advisory Board: BMS, Roche, Roche, MSD, Pfizer, Sanofi; Financial Interests, Personal, Invited Speaker: BMS, MSD, AstraZeneca, Knight, Pfizer; Financial Interests, Personal, Member of Board of Directors: Bradford Hill. F. Rivera Herrero: Financial Interests, Personal and Institutional, Advisory Board: MSD, Lklly, Astellas, BMS, Roche, Amgen, Merck-Serono, Servier; Financial Interests, Personal and Institutional, Invited Speaker: MSD, Lklly, Astellas, BMS, Roche, Amgen, Merck-Serono, Servier, Novartis; Financial Interests, Personal and Institutional, Research Grant: MSD, AstraZeneca, BMS, Amgen, Merck-Serono, Servier, Novartis; Financial Interests, Personal and Institutional, Funding: MSD, AstraZeneca, BMS, Roche, Amgen, Merck-Serono, Servier, Novartis; Financial Interests, Personal and Institutional, Principal Investigator: MSD, AstraZeneca, Amgen, Servier. L. Yu: Financial Interests, Institutional, Full or part-time Employment: Merck & Co.; Financial Interests, Institutional, Stocks/Shares: Merck & Co. S. Shah: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. P. Bhagia: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. L. Shen: Financial Interests, Personal, Other, Consulting fees: Mingji biopharmaceutical, Haichuang pharmaceutical, Herbour biomed; Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, BI, Sanofi, Roche, Servier, AZ; Financial Interests, Institutional, Funding: Beijing Xiantong Biomedical Technology, Qilu Pharmaceutical, ZaiLab Pharmaceutical (Shanghai), Alphamab Oncology, Yaojie Ankang (Nanjing) Technology Co., Ltd., BeiGene, Ltd., Qiyu Biotechnology (Shanghai) Co., Ltd., BriSTAR immunotech; Financial Interests, Institutional, Local PI: Merck Healthcare KGaA, Roche; Financial Interests, Institutional, Trial Chair: Rongchang Pharmaceutical, Innovent, BeiGene, Ltd., NovaRock Biotherapeutics Limited, Qilu Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract